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Steroid hormones are believed to play an important role in prostate carcinogenesis, but epidemiological evidence
linking prostate cancer and steroid hormone genes has been inconclusive, in part due to small sample sizes or
incomplete characterization of genetic variation at the locus of interest. Here we report on the results of a
comprehensive study of the association between HSD17B1 and prostate cancer by the Breast and Prostate Cancer
Cohort Consortium, a large collaborative study. HSD17B1 encodes 17b-hydroxysteroid dehydrogenase 1, an enzyme
that converts dihydroepiandrosterone to the testosterone precursor D5-androsterone-3b,17b-diol and converts estrone
to estradiol. The Breast and Prostate Cancer Cohort Consortium researchers systematically characterized variation in
HSD17B1 by targeted resequencing and dense genotyping; selected haplotype-tagging single nucleotide poly-
morphisms (htSNPs) that efficiently predict common variants in U.S. and European whites, Latinos, Japanese
Americans, and Native Hawaiians; and genotyped these htSNPs in 8,290 prostate cancer cases and 9,367 study-, age-,
and ethnicity-matched controls. We found no evidence that HSD17B1 htSNPs (including the nonsynonymous coding
SNP S312G) or htSNP haplotypes were associated with risk of prostate cancer or tumor stage in the pooled multiethnic
sample or in U.S. and European whites. Analyses stratified by age, body mass index, and family history of disease
found no subgroup-specific associations between these HSD17B1 htSNPs and prostate cancer. We found significant
evidence of heterogeneity in associations between HSD17B1 haplotypes and prostate cancer across ethnicity: one
haplotype had a significant (p , 0.002) inverse association with risk of prostate cancer in Latinos and Japanese
Americans but showed no evidence of association in African Americans, Native Hawaiians, or whites. However, the
smaller numbers of Latinos and Japanese Americans in this study makes these subgroup analyses less reliable. These
results suggest that the germline variants in HSD17B1 characterized by these htSNPs do not substantially influence the
risk of prostate cancer in U.S. and European whites.
Citation: Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, et al. (2005) Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 1(5): e68.
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Prostate cancer is a leading cause of mortality and
morbidity in both western Europe and the United States,
where it is the most commonly diagnosed nondermatological
cancer and is the second leading cause of cancer death in
men. Although epidemiological investigations over several
decades have studied exogenous risk factors for prostate
cancer, including diet, occupation, and sexually transmitted
agents, the only established risk factors for this disease are
age, ethnicity, and family history of prostate cancer.
A large body of evidence suggests that inherited genetic
susceptibility plays an important role in prostate cancer
etiology [1,2]. The risk of prostate cancer in ﬁrst-degree male
relatives of affected individuals is about twice that for the
general population, with greater risks for those with an
increased number of affected family members [3,4]. Twin
studies show that the majority of this excess familial risk is due
to inherited factors [5]. Unlike other cancers, however, high-
penetrance prostate cancer susceptibility genes have not been
consistently identiﬁed. Numerous studies have found sugges-
tive linkage signals, but these have been difﬁcult to replicate.
Similarly, studies of candidate genes suggested by early
linkage studies (e.g., ELAC2, RNASEL, and MSR1)h a v e
provided inconsistent evidence for association [1,2]. Carriers
of mutations in BRCA1 and BRCA2 reportedly have increased
risk of prostate cancer [6,7], but these mutations are rare and
account for only a small fraction of excess familial risk. All of
this evidence suggests multiple common variants that mod-
erately increase prostate cancer risk have yet to be identiﬁed.
Genes encoding proteins involved in hormone biosynthesis
are plausible candidates for such low-penetrance variants.
Steroid hormones are believed to play an important role in
prostate carcinogenesis for several reasons. First, androgens
are essential for prostate maturation and functional integrity.
Second, androgen ablation is standard therapy for metastatic
prostate cancer. Third, androgens are generally needed to
induce prostate cancer in animal models.
The results of studies of serum concentration of androgens
in relation to prostate cancer risk have been somewhat
inconsistent. A meta-analysis of eight prospective serum-
based studies showed modest increases in prostate cancer risk
associated with androstanediol glucuronide levels but not
with testosterone, non–steroid hormone–binding globulin-
bound testosterone, dihydrotestosterone, or androstendione
levels [8], although the largest prospective study found
increased risk with increasing levels of testosterone, after
adjustment for serum sex hormone–binding globulin [9].
One endogenous source of variation in serum or tissue
concentrations of steroid hormones may be functional
variants in genes related to their synthesis and catabolism.
Pursuing this line of reasoning, several investigators have
examined polymorphisms in some of these genes [10–12]. For
example, the missense mutation A49T in the steroid 5a-
reductase type 2 gene (SRD5A2) increases enzyme activity for
converting testosterone to the more potent dihydrotestoster-
one [13]. Several studies found that men who carry the T
allele are at increased risk for prostate cancer, although these
results are not conclusive [14]. Another study found that the T
allele is associated with tumor aggressiveness [15]. Shorter
repeats of the (CAG)n trinucleotide in the androgen receptor
gene (AR) are associated with increased androgen response
gene transactivation and show modest increases in risk in
some, but not all, studies [10,16,17]. The CYP3A4*1B allele has
also been consistently associated with prostate cancer onset
and severity, although the functional impact of this allele
remains controversial [18]. A number of studies have found
evidence that combinations of multiple polymorphisms in
steroid-pathway genes increase risk of prostate cancer
[11,18,19], but these studies have had low power to detect
gene-gene interactions (increasing the likelihood that these
results are due to chance [20]) and to the best of our
knowledge have not been replicated.
Thus, the combined evidence provides several clues about
the role of steroid hormones in prostate cancer yet does not
permit deﬁnitive conclusions, partly because of limitations in
previous epidemiological study designs. Serum hormone
studies are limited because serum levels may not reﬂect
prostate tissue levels, and the studies have generally been
small (case sample sizes have varied from 16 to 222). Further,
hormone interrelationships (e.g., estrogen-androgen balance)
have not been considered in detail. Genetic studies have
assessed only a few of the potentially important gene variants
in similarly underpowered investigations; and gene-gene and
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Synopsis
Steroid hormones such as estrogen and testosterone are hypothe-
sized to play a role in the development of cancer. This is the first
substantive paper from the Breast and Prostate Cancer Cohort
Consortium, a large, international study designed to assess the
effect of variation in genes that influence hormone production and
activity on the risk of breast and prostate cancer. The investigators
first constructed a detailed map of genetic variation spanning
HSD17B1, a gene involved in the production of estrogen and
testosterone. This enabled them to efficiently measure common
variation across the whole gene, capturing information about both
known variants with a plausible function and unknown variants with
an unknown function. Because of the results with a large number of
study participants, the investigators could rule out strong associa-
tions between common HSD17B1 variants and risk of prostate
cancer among U.S. and European whites. While this sheds some light
on the carcinogenic effects of one enzyme involved in the complex
process of steroid hormone production, it remains to be determined
whether variants in other genes play a more important role or if the
combined effects of several genes within these pathways have a
larger impact.T
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HSD17B1 and Prostate Cancergene-environment interrelationships have yet to be effec-
tively examined.
The Breast and Prostate Cancer Cohort Consortium
(BPC3), a large, multicenter collaborative study, aims to
examine the role of steroidal hormones in prostate cancer by
comprehensively measuring variation in more than 30 genes
involved in the steroidal hormone pathway and their
associated receptors in 8,301 prostate cancer cases and
9,373 controls (unpublished data). The BPC3 has adopted a
multistage approach combining genomic, statistical, and
epidemiological methods that involves targeted resequencing
in a multiethnic sample of 190 advanced breast and prostate
cancer cases, followed by genotyping a dense set of common
single nucleotide polymorphisms (SNPs) across a region
spanning the gene in a multiethnic sample of 349 cancer-
free subjects. These genotyping data are used to assess
patterns of linkage disequilibrium and select efﬁcient
haplotype-tagging SNPs (htSNPs), which are then genotyped
on the cases and controls in the main study. The BPC3
provides excellent statistical power to detect modest associ-
ations between common genetic variants and risk of prostate
cancer and to assess the joint effect of genetic variation and
other established risk factors.
Here we report on the association between prostate cancer
and the gene encoding 17b-hydroxysteroid dehydrogenase 1
(17b-HSD-1), HSD17B1, which is situated on chromosome
17q21 near BRCA1. 17b-HSD-1 plays a role in estrogen and
testosterone biosynthesis. We hypothesize that germline
variation in HSD17B1 may lead to variation in 17b-HSD-1
activity. Speciﬁcally, 17b-HSD-1 catalyzes the conversion of
estrone to the more reactive estradiol and may play a role in
the conversion of adrenal-derived dehydroepiandrosterone
to D5-androsterone-3b,17b-diol [21]. D5-Androsterone-
3b,17b-diol has estrogenic activity and peroxisomal prolifer-
ation activity, via peroxisome proliferative activated receptor
a [22]. It also acts as a substrate for conversion to testosterone
by 3b-hydroxysteroid dehydrogenase/D
4-D
5 isomerase. Tes-
tosterone in turn can be metabolized to the more function-
ally active dihydrotestosterone by steroid-5-a-reductase
[21,23]. Dehydroepiandrosterone, estrogens (estrone, estra-
diol), and androgens (testosterone, dihydrotestosterone) are
hormones that affect prostate physiology and possibly
carcinogenesis [24,25]. Thus, increased activity of 17b-HSD-
1 may increase the levels of these hormones and the risk of
prostate cancer. Functionally active 17b-HSD-1 is expressed
in the testis [26], the primary site of testosterone synthesis.
Although initial studies found evidence of HSD17B1 expres-
sion in prostate tissue [21,27], more recent studies of prostate
cancer cell lines have found small amounts of the longer of
the two HSD17B1 transcripts, which does not appear to
correlate with 17b-HSD-1 protein levels [28–32].
While previous studies have evaluated whether germline
variation in HSD17B1 is associated with breast or endometrial
cancer [33–36], this is the ﬁrst large prospective study to
assess HSD17B1 in relation to prostate cancer among men
from several ethnicities.
Results
Table 1 shows demographic and other characteristics of
cases and controls from the seven cohorts. Most study
subjects were U.S. or European whites (75%), followed by
Figure 1. A Scale Map of the 26 SNPs Genotyped in the MEC Screening Panel and a Plot of the Pattern of Linkage Disequilibrium among Them (in
Whites)
The four tag SNPs are markers with arrows, and the block of high linkage disequilibrium and limited haplotype diversity spanning HSD17B1 is
highlighted.
DOI: 10.1371/journal.pgen.0010068.g001
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HSD17B1 and Prostate CancerAfrican Americans (10%), Latinos (7%), Japanese Americans
(5%), and Native Hawaiians (1%). Of the 8,301 prostate
cancer cases and 9,373 controls sent for genotyping, at least
one SNP was successfully genotyped for 8,290 (.99.8%) cases
and 9,367 (.99.9%) controls, with 7,713 (93%) cases and
8,715 (93%) controls genotyped for all four markers. Among
those subjects with data on both genotypes and family history,
832 (14%) cases and 555 (9%) controls reported a father or a
brother with prostate cancer. Cases and controls were
comparable with respect to age, body mass index (BMI [kg/
m
2]), and height. Stage information was available on 71% of
genotyped prostate cancer cases, and among these, 1,312
(22%) had advanced disease (deﬁned as stage C or D disease
at diagnosis or death due to prostate cancer). Gleason score
was recorded for 66% of genotyped cases, with 990 cases
(18% of those with Gleason scores exhibiting scores of eight
or greater).
Resequencing exons in 190 advanced cancer cases identi-
ﬁed two novel nonsynonymous coding SNPs, one of which
was seen more than once. (For more detailed resequencing
results, see Gene_Summary_Table.xls available under
‘‘Genes: Data and Haplotypes’’ at http://www.uscnorris.com/
Core/DocManager/OpenFile.aspx?DocID¼9394.) The latter
SNP and 25 common SNPs spanning a 42-kb region including
HSD17B1 were genotyped in a multiethnic reference panel of
349 cancer-free subjects. Nineteen of these 26 SNPs formed a
block of high linkage disequilibrium (Figure 1) that spans
HSD17B1, including (59 to 39) the pseudogene HSD17BP1, the
promoter region, and the gene TCFL4. We found three
common haplotypes (.5% frequency) within this block
among whites in the reference panel, with a cumulative
frequency above 83% (Table S1). We chose four SNPs that
predict these common haplotypes in whites with a minimum
Rh
2 of 82% (Figure 1 and Table 2); we required that the
nonsynonymous coding SNP S312G (rs605059) be included in
the set of htSNPs. These four htSNPs also predicted common
haplotypes (.5% frequency) in African Americans, Native
Hawaiians, Japanese Americans, and Latinos with a minimum
Rh
2 above 80% (Table S1). However, among African Amer-
icans, the cumulative frequency of common haplotypes was
only 62%. To achieve a cumulative frequency above 70% in
A f r i c a nA m e r i c a n s( i . e . ,t op r e d i c ta na d d i t i o n a lt w o
haplotypes with an Rh
2 .80%), additional htSNPs were
needed. Because we did not genotype these extra SNPs for
this analysis, our current analyses of African Americans are
principally informative for haplotypes with frequency above
5%. None of the SNP genotype frequencies showed evidence
of deviation from Hardy-Weinberg equilibrium at the 0.001
level among controls in any of the cohorts (stratiﬁed by
ethnicity).
Four htSNP haplotypes had frequencies above 5% in white
controls, with a cumulative frequency above 99% (Table 3).
Haplotype frequencies were similar for whites across cohorts
(Table S2), while some differences in haplotype frequencies
were seen among whites, African Americans, Japanese
Americans, and Native Hawaiians. Consistent with the greater
genetic diversity in African Americans, we found one
haplotype (CAAC) that was common only in African
Americans (Table 3).
Global tests of association between HSD17B1 haplotypes
and prostate cancer were not signiﬁcant (likelihood-ratio test
[LRT] v
2 ¼ 5.25, 5 d.f., p ¼ 0.39 for analysis using all subjects;
LRT v
2¼6.45, 5 d.f., p¼0.22 for analysis restricted to whites;
see Table 4). However, the test for heterogeneity in haplotype
odds ratios across ethnicities was signiﬁcant (LRT v
2 ¼ 44.66,
15 d.f., p , 0.0001). While no haplotype showed evidence of
association with prostate cancer risk in African Americans,
whites, or Native Hawaiians, haplotype CAGC was signiﬁ-
cantly associated with decreased prostate cancer risk in
Latinos and Japanese Americans (Figure 2; more detailed
cohort- and ethnicity-speciﬁc results are given in Table S3).
The test for heterogeneity across cohorts in haplotype odds
ratios among whites was not signiﬁcant (LRT v
2 ¼ 37.82, 23
d.f., p ¼ 0.03).
Genotype-speciﬁc odds ratios for the four SNPs tested are
shown in Table 5 for analyses restricted to whites and for
analyses pooling all subjects. There was no evidence of an
association between the nonsynonymous S312G SNP and
prostate cancer (p¼0.40 for analysis using all subjects and p¼
0.09 for analysis restricted to whites). None of the other SNPs
Table 2. Characteristics of the htSNPs for HSD17B1
SNP rs676387 rs605059 rs598126 rs2010750
Base change C . AA . GG . AC . T
Cohort Freq
a Freq Freq Freq
ACS 0.28 0.46 0.46 0.41
ATBC 0.23 0.47 0.47 0.38
EPIC 0.28 0.48 0.48 0.43
Italy 0.24 0.61 0.61 0.52
Spain 0.28 0.54 0.56 0.50
England 0.26 0.47 0.47 0.42
The Netherlands 0.32 0.50 0.48 0.44
Greece 0.21 0.50 0.50 0.46
Germany 0.26 0.50 0.50 0.45
Sweden 0.36 0.36 0.26 0.34
HPFS 0.26 0.46 0.46 0.42
MEC–African Americans 0.19 0.52 0.57 0.23
MEC–Native Hawaiians 0.57 0.34 0.34 0.33
MEC–Japanese 0.43 0.54 0.54 0.52
MEC–Latinos 0.21 0.50 0.51 0.43
MEC–Whites 0.31 0.48 0.48 0.44
PHS 0.25 0.48 0.48 0.43
PLCO–African American 0.20 0.51 0.57 0.23
PLCO–White 0.25 0.47 0.47 0.42
More details on these SNPs and genotyping quality control are available at www.uscnorris.com/MECGenetics/
CohortGCKView.aspx.
aFrequency of the allele with the lower frequency in all controls.
DOI: 10.1371/journal.pgen.0010068.t002
Table 3. Haplotype Frequencies in Controls, by Ethnicity
Haplotype
a Whites African
Americans
Latinos Japanese
Americans
Native
Hawaiians
CGAT 0.402 0.227 0.400 0.525 0.316
CAGC 0.272 0.228 0.315 0.055 0.088
AAGC 0.259 0.187 0.198 0.404 0.581
CGAC 0.060 0.288 0.076 0.016 0.015
CAAC 0.000 0.065 0.003 0.000 0.000
All with ,5%
frequency
0.006 0.004 0.007 0.000 0.000
aAlleles listed for htSNPs in 59 to 39 order: rs676387, rs605059, rs598126, rs2010750.
DOI: 10.1371/journal.pgen.0010068.t003
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HSD17B1 and Prostate Cancershowed any evidence of association with prostate cancer at the
0.01 level, and none of the SNP odds ratios showed signiﬁcant
evidence of heterogeneity across ethnicity (Table S4).
We calculated stratum-speciﬁc SNP and haplotype odds
ratios for strata deﬁned by family history (at least one ﬁrst-
degree relative diagnosed with prostate cancer versus none),
age at time of diagnosis or time of diagnosis of the matched
case for controls ( 65 versus .65 years old), and BMI (,25,
 25 but ,30, .30). None of these stratum-speciﬁc tests of
association were signiﬁcant at the 0.01 level, and tests for
departures from multiplicative interaction model (tests for
‘‘statistical interaction’’) were also nonsigniﬁcant (Tables S5
and S6).
We also found no association between HSD17B1 haplotypes
and advanced prostate cancer (Table 6).
Discussion
After comprehensively screening HSD17B1 for variation in
U.S. and European whites, we found no evidence of
association between prostate cancer and common variants
in HSD17B1. We observed that haplotype odds ratios for
association with prostate cancer differed across ethnicity,
with the CAGC haplotype showing a signiﬁcant (p , 0.01)
inverse association with prostate cancer effects in Latinos and
Japanese Americans. However, the smaller sample size in
these subgroups limits our power to detect an effect of the
observed magnitude, leading to an increase in the probability
that these results are false positives. We found no evidence
that the odds ratios associated with common haplotypes or
SNPs differed by cohort (among whites), family history, age,
or BMI. We also found no evidence that common variants in
HSD17B1 were related to disease severity among cases.
A major advantage of the BPC3 haplotype-tagging ap-
proach is that it allows a cost-effective approach to the
identiﬁcation of common susceptibility alleles across the
entire gene region. This includes putative functional variants
such as nonsynonymous coding SNPs as well as variants of
unknown function in intronic and 59 and 39 untranslated
regions. In the case of HSD17B1, there is evidence that several
upstream regions participate in the regulation of HSD17B1
expression [28]. All of these lie well within the region of high
linkage disequilibrium spanning HSD17B1; hence, common
variants in these regulatory regions are accurately predicted
by the four htSNPs analyzed here.
Another major strength of the BPC3 is its unprecedented
sample size. With 8,290 cases and 9,367 controls, there is
greater than 90% power to detect a dominant or log-additive
odds ratio of 1.3 for an allele with 5% frequency at the 0.001
level, even after accounting for loss of effective sample size
due to the haplotype-tagging approach. The large sample size
of the BPC3 allows adequately powered investigation of
differences in genetic effect by established or hypothesized
prostate cancer risk factors. For example, there is still greater
than 90% power to detect a stratum-speciﬁc dominant odds
ratio of 1.7 for a 5% frequency variant at the 0.001 level when
the stratum consists of only 20% of the total sample.
A limitation of the study is the inability of the assayed
htSNPs to adequately capture several haplotypes in African
Americans that have a frequency just below 5%, so the
cumulative frequency of the haplotypes that are effectively
predicted in this group by the htSNPs is only 60%. Moreover,
Table 4. HSD17B1 Haplotypes and Prostate Cancer Risk, BPC3
Subjects Haplotype
a Units Zero Copies One Copy Two Copies Heterogeneity p-Value
b
All subjects: global CGAT Controls/cases 3,607/3,227 4,237/3,747 1,522/1,316 0.03
v
2 ¼ 5.25 on 5 d.f., p ¼ 0.39 OR (99% CI) 1.00 (ref) 0.97 (0.89, 1.06) 0.94 (0.84,1.06)
CAGC Controls/cases 5,221/4,664 3,469/3,018 677/608 ,0.0001
OR (99% CI) 1.00 (ref) 0.98 (0.89, 1.06) 1.02 (0.87, 1.19)
AAGC Controls/cases 5,206/4,477 3,495/3,184 665/628 0.53
OR (99% CI) 1.00 (ref) 1.05 (0.97, 1.15) 1.09 (0.93, 1.28)
CGAC Controls/cases 7,947/7,073 1,286/1,110 134/107 0.57
OR (99% CI) 1.00 (ref) 1.00 (0.88, 1.13) 0.97 (0.67, 1.38)
CAAC
c Controls/cases 9,232/8,193 128/94 7/3 0.69
OR (99% CI) 1.00 (ref) 0.93 (0.63, 1.37) 0.53 (0.08, 3.39)
All others Controls/cases 9,260/8,192 105/95 2/3 0.45
OR (99% CI) 1.00 (ref) 1.09 (0.74, 1.62) 2.23 (0.11, 44.45)
Whites: global CGAT Controls/cases 2,578/2,393 3,290/2,843 1,194/986 0.30
v
2 ¼ 6.95 on 5 d.f., p ¼ 0.22 OR (99% CI) 1.00 (ref) 0.92 (0.84, 1.02) 0.89 (0.78, 1.02)
CAGC Controls/cases 3,758/3,281 2,765/2,428 539/514 0.02
OR (99% CI) 1.00 (ref) 1.00 (0.91, 1.10) 1.10 (0.93, 1.31)
AAGC Controls/cases 3,890/3,353 2,686/2,435 486/435 0.01
OR (99% CI) 1.00 (ref) 1.05 (0.96, 1.16) 1.05 (0.88, 1.26)
CGAC Controls/cases 6,253/5,487 767/694 42/42 0.87
OR (99% CI) 1.00 (ref) 1.02 (0.88, 1.18) 1.17 (0.66, 2.08)
CAAC Controls/cases 7,055/6,216 7/7 0/0 —
OR (99% CI) 1.00 (ref) 1.29 (0.28, 5.90) —
All others Controls/cases 6,976/6,141 85/79 2/3 0.12
OR (99% CI) 1.00 (ref) 1.11 (0.72, 1.71) 2.21 (0.11, 43.95)
aAlleles listed for htSNPs in 59 to 39 order: rs676387, rs605059, rs598126, rs2010750.
bp-Value for LRT of heterogeneity of ORs across ethnicity (all subjects) or study (whites).
cHaplotype only common among African Americans (MEC and PLCO).
CI, confidence interval; OR, odds ratio.
DOI: 10.1371/journal.pgen.0010068.t004
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HSD17B1 and Prostate Cancerpower to detect possible associations between prostate cancer
and genetic variation in HSD17B1 unique to nonwhite
ethnicities is limited in this study, given the smaller sample
sizes available for these groups. For example, power to detect
the observed log-additive effect sizes for haplotype CAGC in
Japanese Americans at the 0.01 level is approximately 59%
(68% for Latinos). Thus, assuming prior probabilities of
causality for this HSD17B1 haplotype of 1%, the false-positive
probabilities for these associations are 64% for Japanese
Americans and 59% for Latinos; assuming a more conserva-
tive prior probability of 0.1%, the false-positive probabilities
are 95% for Japanese Americans and 94% for Latinos.
Further analysis to assess whether HSD17B1 is associated with
risk for prostate cancer in nonwhite ethnic groups will
require larger samples accumulated through longer follow-up
or new cohorts.
Another potential limitation of this study is that results are
reported for a single gene. Prostate cancer risk may be a
complex function of genotypes across several genes involved
in steroid hormone metabolism [37]. For example, a mutation
in one gene may only increase risk in the presence of a
mutation in a different gene. Although a gene involved in
such gene-gene interactions can be discovered using a
marginal test (ignoring the other genes) [38], incorporating
information about other genes may improve power to detect
association [39]. As the BPC3w i l le v e n t u a l l ym e a s u r e
variation in over 30 genes related to the steroid hormone
pathway, it will have the opportunity to investigate the
combined contribution of multiple genes to the risk of
prostate cancer.
In the present study, the absence of an association between
HSD17B1 haplotypes and prostate cancer suggests that we can
rule out large or moderate associations between common
HSD17B1 variants and risk of prostate cancer among U.S. and
European whites. If any variants affect the risk of prostate
cancer, they are likely to have small effects or low frequency
and are unlikely to contribute signiﬁcantly to the overall
incidence of prostate cancer in these populations. While this
sheds some light on the clinical effects of one enzyme
involved in the complex process of steroid synthesis and
catabolism, it remains to be determined whether variants in
other genes in steroidal hormone pathways play a more
important role or if the combined effects of several genes
within these pathways have a larger impact. The BPC3 plans
to investigate these questions by comprehensively measuring
Figure 2. Plot of Log Odds Ratios for CAGC (Relative to All Other
Haplotypes) under an Additive Model
The boxes are proportional to the inverse of the parameter estimate
variance; larger boxes denote more precise estimates. The error bars
mark 99% confidence intervals.
DOI: 10.1371/journal.pgen.0010068.g002
Table 5. HSD17B1 htSNPs and Prostate Cancer Risk, BPC3
Subjects SNP Units Homozygote
Major Allele
Heterozygote Homozygote
Minor allele
p-Value
a Heterogeneity
p-Value
b
All subjects rs676387 C . A Controls/cases 5,118/4,396 3,452/3,131 667/634 0.16 0.60
OR (99% CI) 1.00 (ref) 1.05 (0.96, 1.14) 1.10 (0.94, 1.29)
rs605059 A . G Controls/cases 2,521/2,299 4,409/3,932 2,141/1,845 0.40 0.04
OR (99% CI) 1.00 (ref) 0.97 (0.88, 1.07) 0.94 (0.84, 1.05)
rs598126 G . A Controls/cases 2,466/2,255 4,461/3,965 2,228/1,897 0.26 0.03
OR (99% CI) 1.00 (ref) 0.96 (0.88, 1.06) 0.93 (0.83, 1.04)
rs2010750 C . T Controls/cases 3,380/3,033 4,241/3,741 1,551/1,314 0.21 0.02
OR (99% CI) 1.00 (ref) 0.97 (0.88, 1.06) 0.92 (0.82, 1.04)
Whites rs676387 C . A Controls/cases 3,817/3,287 2,648/2,388 485/438 0.38 0.01
OR (99% CI) 1.00 (ref) 1.05 (0.95, 1.15) 1.06 (0.89, 1.27)
rs605059 A . G Controls/cases 1,941/1,824 3,350/2,930 1,538/1,310 0.09 0.86
OR (99% CI) 1.00 (ref) 0.93 (0.83, 1.03) 0.91 (0.80, 1.03)
rs598126 G . A Controls/cases 1,948/1,811 3,370/2,957 1,554/1,306 0.11 0.80
OR (99% CI) 1.00 (ref) 0.94 (0.84, 1.05) 0.90 (0.79, 1.03)
rs2010750 C . T Controls/cases 2,374/2,230 3,293/2,848 1,226/990 0.01 0.96
OR (99% CI) 1.00 (ref) 0.92 (0.83, 1.02) 0.86 (0.76, 0.99)
ap-Value from 2 d.f. LRT for association.
bp-Value for LRT of heterogeneity of odds ratios across ethnicity (all subjects) or study (whites).
DOI: 10.1371/journal.pgen.0010068.t005
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HSD17B1 and Prostate Cancervariation in more than 30 genes involved in the steroidal
hormone pathway and their associated receptors. Last, this
study underscores the importance of large, cooperative
consortia in evaluating the contribution of germline genetic
variation to a common cancer, such as prostate cancer.
Materials and Methods
Study population. The BPC3 has been described in detail elsewhere
(unpublished data). For prostate cancer, the study combines the
resources of seven large cohort studies of men: the American Cancer
Society Cancer Prevention Study II (ACS CPS-II) [40], the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study [41],
the EPIC Cohort (itself comprising cohorts from Denmark, Great
Britain, Germany, Greece, Italy, the Netherlands, Spain, and Sweden)
[42], the Health Professionals Follow-up Study (HPFS) [43], the
Hawaii/Los Angeles Multi-ethnic Cohort Study (MEC) [44], the
Physicians Health Study (PHS) [45], and the Prostate, Lung, Color-
ectal, and Ovarian (PLCO) Cancer Screening Trial [46]. With the
exception of the MEC, these cohorts are composed predominantly of
whites of European descent. We do not have information on ethnicity
or ancestry beyond country of residence for EPIC and have classiﬁed
all EPIC participants as white. We anticipate that the number of EPIC
participants of non-European ancestry is small. We plan further
population genetic studies will to verify this, using the large number
of SNPs the BPC3 will have genotyped. The MEC contributes African
American, Latino, Japanese Americans, and Native Hawaiian cases
and controls recruited from Los Angeles and Hawaii. The PLCO also
includes over 650 African American subjects. We distinguish Spanish
EPIC participants from MEC Latino participants, because the latter
are principally of Mexican and Central American origin, with origins
in European, Native American, and African populations [47,48].
Cases of prostate cancer were identiﬁed through population-based
cancer registries or self-report conﬁrmed by medical records. The
BPC3 data for prostate cancer consist of a series of matched nested
case-control studies from each cohort; controls were matched to
cases on a number of potentially confounding factors, including age,
ethnicity, and region of recruitment. For the current investigation,
prostate cancer cases were matched to available controls by age in 5-
year intervals, ethnicity, and cohort.
SNP discovery and htSNP selection. We used a multistage
approach to characterize genetic variation in and around HSD17B1
in our large sample of cases and controls. First, HSD17B1 exons in 190
advanced breast and prostate cancer cases were resequenced at the
Broad Institute to discover novel coding SNPs. Then we genotyped a
set of SNPs across a 42-kb region spanning HSD17B1 in a multiethnic
reference sample to determine patterns of linkage disequilibrium and
select htSNPs. This set consisted of 25 common (allele frequency
.5%) SNPs selected from public databases and one nonsynonymous
SNP discovered during resequencing; these 26 SNPs covered the
target region at a density of one SNP per 1.6 kb. The target region
included the gene N-acetylglucosaminidase alpha (NAGLU) and the
pseudogene for HSD17B1 (HSD17BP1), both 59 of HSD17B1, and
coenzyme A synthase (COASY) and transcription factor-like 4 (TCFL4),
both 39 of HSD17B1 (see Figure 1). The reference sample consisted of
equal numbers (70 each) of whites, African Americans, Latinos, and
Japanese Americans and 69 Native Hawaiians.
We identiﬁed a region of high linkage disequilibrium and low
haplotype diversity spanning HSD17B1 using the algorithm of Gabriel
et al. [49] as implemented in Haploview [50]. Haplotype-tagging SNPs
were then chosen in these regions based on Rh
2, a measure of the
correlation between observed haplotypes and those predicted on the
basis of htSNP genotypes [51]. This approach is based on the
observation that within blocks of high linkage disequilibrium and
limited haplotype diversity, common SNPs are highly correlated with
common haplotypes [49]. Finally, we genotyped these htSNPs in BPC3
cases and controls and tested for association between htSNP
haplotypes and disease.
Genotyping. The 26 SNPs were genotyped in the multiethnic
reference panel at the Broad Institute using Sequenom and Illumina
platforms. Genotyping of cases and controls was performed in 4
laboratories using a ﬂuorescent 59 endonuclease assay and ABI
PRISM 7900 for sequence detection (TaqMan; Applied Biosystems,
Foster City, California, United States). Based on sequence informa-
tion, TaqMan assays were designed for each SNP and synthesized in
four separate batches of 12,000 reactions for the roughly 48,000
Table 6. HSD17B1 Haplotypes and Risk of Advanced Stage ( C) and High-Grade (Gleason  8) Prostate Cancer among All Cases
Cancer Type Haplotype
a Units Zero Copies One Copy Two Copies Heterogeneity
p-Value
b
Advanced stage CGAT Adv./non-adv. 522/1,725 584/2,066 206/768 0.84
(global v
2 ¼ 4.76 on 5 d.f., p ¼ 0.45) OR (99% CI) 1.00 (ref) 0.92 (0.76, 1.10) 0.90 (0.70, 1.16)
CAGC Adv./non-adv. 735/2,627 481/1,623 97/309 0.54
OR (99% CI) 1.00 (ref) 1.01 (0.84, 1.22) 1.04 (0.74, 1.47)
AAGC Adv./non-adv. 721/2,493 488/1,720 103/347 0.89
OR (99% CI) 1.00 (ref) 1.00 (0.83, 1.20) 1.15 (0.83, 1.60)
CGAC Adv./non-adv. 1,104/3,887 187/611 21/61 0.83
OR (99% CI) 1.00 (ref) 1.08 (0.84, 1.39) 1.30 (0.64, 2.62)
CAAC
c Adv./non-adv. 1,301/4,490 10/67 1/2 —
OR (99% CI) 1.00 (ref) 0.53 (0.20, 1.38) 2.40 (0.10, 57.62)
All others Adv./non-adv. 1,294/4,502 17/54 1/2 —
OR (99% CI) 1.00 (ref) 0.82 (0.36, 1.83) 1.29 (0.01, 115.99)
High grade CGAT Gleason  8/,8 345/1,743 467/2,003 178/732 0.11
(global v
2 ¼ 10.36 on 5 d.f., p ¼ 0.07) OR (99% CI) 1.00 (ref) 1.11 (0.90, 1.37) 1.13 (0.85, 1.49)
CAGC Gleason  8/,8 637/2,536 291/1,635 62/308 0.61
OR (99% CI) 1.00 (ref) 0.82 (0.66, 1.02) 0.96 (0.64, 1.42)
AAGC Gleason  8/,8 514/2,467 400/1,669 76/342 0.89
OR (99% CI) 1.00 (ref) 1.08 (0.88, 1.32) 0.86 (0.59, 1.25)
CGAC Gleason  8/,8 833/3,797 141/615 16/67 0.08
OR (99% CI) 1.00 (ref) 1.13 (0.85, 1.50) 1.20 (0.56, 2.59)
CAAC
c Gleason  8/,8 984/4,403 5/73 1/2 —
OR (99% CI) 1.00 (ref) 0.29 (0.08, 1.00) 1.97 (0.08, 46.38)
All others Gleason  8/,8 978/4,418 12/58 0/2 —
OR (99% CI) 1.00 (ref) 1.10 (0.44, 2.75) —
aAlleles listed for htSNPs in 59 to 39 order: rs676387, rs605059, rs598126, rs2010750.
bp-Value for LRT of heterogeneity of ORs across ethnicity.
cHaplotype common only among African Americans (MEC and PLCO).
CI, confidence interval; OR, odds ratio.
DOI: 10.1371/journal.pgen.0010068.t006
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HSD17B1 and Prostate Cancerneeded to complete the study of HSD17B1 in BPC3 breast and
prostate cancer samples. Initial quality control was performed at the
manufacturer (Applied Biosystems); an additional 500 test reactions
were run by the Cohort Consortium on the multiethnic reference
panel; greater than 99.5% concordance was observed across
genotyping platforms. (Assay characteristics for the four htSNPs for
HSD17B1 are available on the public Website: http://www.uscnorris.
com/mecgenetics/CohortGCKView.aspx.) Sequence validation for
each SNP assay was performed and 100% concordance observed
(http://snp500cancer.nci.nih.gov) [52]. To assess interlaboratory var-
iation, each center ran assays on a designated set of 94 samples from
the SNP 500 cancer panel, showing completion and concordance
rates of greater than 99% [52]. The internal quality of genotype data
at each center was assessed by 5% to 10% blinded samples in
duplicate or triplicate (depending on study).
Statistical analysis. For each SNP, we used conditional logistic
regression to simultaneously estimate the odds ratio for disease
associated with carrying one copy of the minor allele relative to
carrying no copies and the odds ratio associated with carrying two
copies relative to carrying no copies. We estimated haplotype-speciﬁc
odds ratios using an expectation-substitution approach to account
for haplotype uncertainty given unphased genotype data [53,54].
Haplotype frequencies and subject-speciﬁc expected haplotype
indicators were calculated separately for each cohort (and country
or ethnicity within cohort). To test the global null hypothesis of no
association between variation in HSD17B1 haplotypes and risk of
prostate cancer, we used an LRT comparing a model with additive
effects on the log odds scale for each common haplotype (treating the
most common haplotype as the referent) to the intercept-only model.
We considered haplotypes with greater than 5% frequency in at least
one cohort or ethnic group to be ‘‘common.’’ All other haplotypes
were pooled into a separate ‘‘rare haplotypes’’ category.
Although the matched analysis accounts for heterogeneity in risk-
factor prevalence across study, we also tested for heterogeneity in
odds ratio estimates across studies that might result from slightly
different matching criteria or case deﬁnitions using an LRT. We also
tested for heterogeneity in odds ratio estimates across ethnicity using
an LRT that compares the model with common additive effects for
each haplotype (except the referent) to the model with distinct
additive effects for each ethnicity where the expected numbers of the
haplotype in cases and controls under the null were above ﬁve. Thus,
the three common haplotypes among Native Hawaiians contributed
two ethnicity-speciﬁc haplotype effects; the ﬁve common haplotypes
and the pooled rare haplotypes among African Americans contribute
ﬁve. To assess whether other risk factors for prostate cancer modify
the association with haplotype, we calculated risk stratum–speciﬁc
odds ratios and tested for departures from a multiplicative
interaction model. We performed case-only analyses to test for
association between HSD17B1 variants and advanced prostate cancer
(as deﬁned above).
We calculated 99% conﬁdence intervals and test for signiﬁcance
associations at the 0.01 level to minimize the chance of both false-
positive and false-negative results. An upper bound on the
probability of a false positive was estimated roughly as a(1 – p)/[a(1
– p) þ p(1 – b)], where p is the prior probability that a variant has a
relative risk of R or greater, a is the test size, and 1 – b is the power
[20]. Our study has greater than 99% power to detect a dominant or
log-additive odds ratio of 1.3 for an allele with 5% frequency at the
0.001 level. Thus, when a ¼ 0.01, the probability of a false positive is
8% for the very optimistic prior probability of a 10% chance that
HSD17B1 is associated with prostate cancer. The false-negative report
probability, deﬁned as bp /[(1 – a)(1 – p) þ pb ], is only 0.1% in this
situation. For a prior probability of 1 in 100, the false-positive and
false-negative report probabilities are 50% and 0.01%, respectively.
Thus, for a range of priors, the probability that we would fail to reject
at the .01 level if HSD17B1 were truly associated with disease is small.
Power for individual SNPs and haplotypes was calculated using
Quanto (http://hydra.usc.edu/gxe/), assuming an effective sample size
of NR h
2 to adjust for the loss in power inherent in genotyping
surrogate tagging SNPs. Here N is the nominal sample size and Rh
2 is
the design threshold of 0.8; this is somewhat conservative, as the
achieved Rh
2 can be well above the threshold.
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Note Added in Proof
The Breast and Prostate Cancer Cohort Consortium (BPC3) study, cited in
this paper as unpublished data, is now in press [55].
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